Interestingly, the AXL-targeting agent, Enapotamab vedotin (EnaV), which is an antibody-drug conjugate (ADC), was found to stimulate the release of DAMPs in human models of lung cancer and melanoma (187). This evidence concerns the gene AXL and lung carcinoma.